Transoma Medical
This article was originally published in The Gray Sheet
Executive Summary
Sleuth AT advanced trending wireless, implantable cardiac monitoring system is rolling out after gaining 510(k) clearance Feb. 11, St. Paul, Minn., company announces March 4. Sleuth AT is a second-generation system that "allows physicians to program the capture of high quality electrocardiogram strips at frequent intervals, providing a new level of insight into complex arrhythmias which are often asymptomatic and frequently changing," according to Transoma. The first incarnation of Sleuth debuted in 2007
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.